Revolution Medicines (RVMD) Accounts Payables (2019 - 2026)

Revolution Medicines' Accounts Payables history runs 8 years deep, the most recent figure standing at $80.5 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 69.53% year-over-year to $80.5 million; the TTM figure through Mar 2026 stood at $80.5 million (up 69.53% YoY), while the FY2025 annual figure was $64.6 million, up 18.72% from the prior year.
• Accounts Payables was $80.5 million for Q1 2026 at Revolution Medicines, up from $64.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $80.5 million in Q1 2026 to a low of $14.1 million in Q2 2022.
• Historically, Accounts Payables has averaged $40.0 million across 5 years, with a median of $29.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables fell 17.45% in 2024, then surged 206.06% in 2025.
• A 5-year view of Accounts Payables shows it stood at $21.3 million in 2022, then surged by 190.0% to $61.8 million in 2023, then dropped by 11.91% to $54.4 million in 2024, then grew by 18.72% to $64.6 million in 2025, then grew by 24.64% to $80.5 million in 2026.
• The last three Accounts Payables figures came in at $80.5 million (Q1 2026), $64.6 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.